Protara Therapeutics, Inc.: current liabilities
Current liabilities for Protara Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Protara Therapeutics, Inc. financial histories
What this measure means
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
Exact concept: us-gaap:LiabilitiesCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 10,939,000 | USD | 2026-03-10 | 10-K · 0001213900-26-025433 |
| At date | 2024-12-31 | 10,961,000 | USD | 2026-03-10 | 10-K · 0001213900-26-025433 |
| At date | 2023-12-31 | 6,149,000 | USD | 2025-03-05 | 10-K · 0001213900-25-020368 |
| At date | 2022-12-31 | 5,740,000 | USD | 2024-03-13 | 10-K · 0001213900-24-021982 |
| At date | 2021-12-31 | 4,298,000 | USD | 2023-03-08 | 10-K · 0001213900-23-018373 |
| At date | 2020-12-31 | 2,915,000 | USD | 2022-03-09 | 10-K · 0001213900-22-011208 |
| At date | 2019-12-31 | 3,351,000 | USD | 2021-03-11 | 10-K · 0001213900-21-014709 |
| At date | 2018-12-31 | 3,078,000 | USD | 2020-03-20 | 10-K · 0001171843-20-001860 |
| At date | 2017-12-31 | 9,240,000 | USD | 2019-03-13 | 10-K · 0001171843-19-001687 |
| At date | 2016-12-31 | 5,079,000 | USD | 2018-03-14 | 10-K · 0001171843-18-001934 |
| At date | 2015-12-31 | 4,133,000 | USD | 2017-03-16 | 10-K · 0001171843-17-001555 |
| At date | 2014-12-31 | 2,338,000 | USD | 2016-03-14 | 10-K · 0001171843-16-008541 |
| At date | 2013-12-31 | 9,768,000 | USD | 2015-03-20 | 10-K · 0001171843-15-001528 |
Related financial histories
- Protara Therapeutics, Inc.: total assets
- Protara Therapeutics, Inc.: total liabilities
- Protara Therapeutics, Inc.: stockholders equity
- Protara Therapeutics, Inc.: cash and cash equivalents
- Protara Therapeutics, Inc.: net income or loss
- Protara Therapeutics, Inc.: operating cash flow
- Protara Therapeutics, Inc.: capital expenditure payments
- Protara Therapeutics, Inc.: financing cash flow
- Protara Therapeutics, Inc.: investing cash flow
- Protara Therapeutics, Inc.: retained earnings or deficit
- Protara Therapeutics, Inc.: basic weighted-average shares
- Protara Therapeutics, Inc.: diluted weighted-average shares
- Protara Therapeutics, Inc.: basic earnings per share
- Protara Therapeutics, Inc.: diluted earnings per share
- Protara Therapeutics, Inc.: income tax expense or benefit
- Protara Therapeutics, Inc.: net property, plant and equipment
- Protara Therapeutics, Inc.: share-based compensation expense
- Protara Therapeutics, Inc.: operating income or loss
- Protara Therapeutics, Inc.: current assets
- Protara Therapeutics, Inc.: interest expense
- Protara Therapeutics, Inc.: current accounts payable
- Protara Therapeutics, Inc.: goodwill carrying amount
- Protara Therapeutics, Inc.: common-stock repurchase payments
- Protara Therapeutics, Inc.: operating expenses
- Protara Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Protara Therapeutics, Inc. / CIK 0001359931
- Captured
- 2026-09-20T07:55:59.662Z
- SEC response SHA-256
73c5c8e9513bdc55c707e83d9669fc2bd4dbb1b11805f8d13591997b9e86c1c4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001359931.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))